Immunome, Inc. is a clinical-stage biotechnology company focused on developing targeted oncology therapies. The company's pipeline includes varegacestat, an oral gamma secretase inhibitor for desmoid tumors, which is in Phase 3 trials; IM-1021, a ROR1 antibody-drug conjugate in Phase 1 trials for B-cell lymphoma; and IM-3050, a fibroblast activation protein targeted radioligand therapy. Preclinical assets include solid tumor antibody-drug conjugates such as IM-1617, IM-1340, and IM-1335. Immunome utilizes its internal discovery capabilities to design antibody-drug conjugates against novel targets, supported by the HC74 topoisomerase 1 inhibitor payload. The company acquired varegacestat from Ayala Pharmaceuticals in March 2024 and formed through the merger of Morphimmune and Immunome in October 2023. Its leadership team has experience in developing and commercializing antibody-drug conjugates for lymphoma, urothelial cancer, and cervical cancer.

Summarised from the company's own disclosures, fiscal year ended Mar 2026

Industry Biotechnology Homepage immunome.com
Sector Healthcare IR page investors.immunome.com
Tags
oncology, antibody-drug conjugates, gamma secretase inhibitors, radioligand therapy, desmoid tumors, b-cell lymphoma, solid tumors, topoisomerase 1 inhibitors, targeted therapies, Varegacestat, AL102, IM-1021, IM-3050, IM-1617, IM-1340, IM-1335, HC74, Ayala Pharmaceuticals, Morphimmune
Press page investors.immunome.com/news-releases

Metrics

Valuation  
Market cap $ 2.445B
Market cap (USD) $ 2.445B
P/E -8.12
PEG —
P/BV 5.38
P/S 352.19
P/OCF -10.67
P/FCF -10.24
Dividend yield —
Turnover / mcap —
Returns  
ROE -52.1%
ROI —
ROIC —
Profit margin -3,060.0%
Growth  
Revenue growing No
Profits growing No
Revenue up 3y —
Revenue up 5y —
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable No
Margin expanding No
Buying back stock No
Diluting (TTM) Yes
Debt/Equity —
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 66
Quality score -76.9%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019
Revenue 6.941M 9.041M 14.018M — — — —
Net profit -212.394M -292.963M -106.806M -36.896M -24.711M -17.8M -10.444M
Free cash flow -200.604M -117.967M -8.399M -28.938M -18.305M -12.72M -9.833M

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019
Share price 21.48 10.62 10.7 2.21 12.96 9.68 —
Price performance 12m 1.02 -0.01 3.84 -0.83 0.34 — —

Filed figures

Figure Dec 2018 Dec 2019 Dec 2020 Dec 2021 Dec 2022 Dec 2023 Dec 2024 Dec 2025
Balance sheet detail
Borrowings, current (USD) — — 366,000 — — — — —
Borrowings, non-current (USD) — — 134,000 — — — — —
Lease liabilities (USD) — 239,000 — 200,000 — 1.34M 4.83M 3.86M
Cash and deposits (USD) 1.7M 2.54M 39.8M 49.2M 20.3M 98.7M 143M 653M
Right-of-use assets (USD) — — — 200,000 284,000 1.56M 4.28M 2.98M
Net debt (borrowings + leases - cash) (USD) — — -39.3M — — — — —
Cash flow detail
Operating cash flow (USD) — -9.6M -12.1M -18.2M -28.7M -7.57M -111M -191M
Purchases of property, plant and equipment (USD) — -233,000 -586,000 -79,000 -248,000 -831,000 -7.17M -9.69M
Change in payables (cash effect) (USD) — 75,000 504,000 1.78M -677,000 -608,000 9.53M -9.16M
Interest paid (cash effect) (USD) — -106,000 -29,000 -14,000 — — — —
Share-based compensation (USD) — 14,000 621,000 3.45M 5.33M 6.22M 15.7M 25.7M
Free cash flow (OCF - PPE - intangibles) (USD) — -9.83M -12.7M -18.3M -28.9M -8.4M -118M -201M
Income detail
Research and development expense (USD) — 8.82M 7.49M 14.1M 23.3M 23.1M 130M 177M
↳ 5y CAGR +71.1% +88.3%
Total comprehensive income (USD) — — — — -37.5M -107M -293M -212M
Comprehensive income to owners (USD) — — — — -37.5M -107M -293M -212M
Reported Nov 16, 2020 Mar 25, 2021 Mar 25, 2021 May 12, 2022 Mar 28, 2024 May 14, 2024 Mar 19, 2025 Mar 3, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

On November 9, 2026, Immunome, Inc. (the “Company”) announced its financial results for the third quarter ended September 30, 2026 and provided a business update in the press release attached hereto as Exhibit 99.1 and incorporated herein by reference. The information shall not be deemed incorporated by reference into any other filing with the Securities and Exchange Commission made by the Company, whether made before or after today’s date, regardless of any general incorporation language in such filing, except as shall be expressly set forth by specific references in such filing.

NEWS DETAILS

View all news

Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

November 6, 2026

BOTHELL, Wash. – Immunome, Inc. (the “Company”) (Nasdaq: IMNM), a clinical-stage targeted oncology company focused on developing first-in-class and best-in-class cancer therapies, announced today that on November 2, 2026, the Compensation Committee of the Company’s Board of Directors (the “Compensation Committee”) granted inducement awards consisting of non-statutory stock options to purchase an aggregate of 206,700 shares of common stock and 103,350 restricted stock units (“RSUs”) to seventeen new employees under the Company’s 2024 Inducement Plan. The Compensation Committee approved the awards as an inducement material to such employees’ employment in accordance with Nasdaq Listing Rule 5635(c)(4).

Each stock option has an exercise price per share equal to $19.59, the Company’s closing sales price on November 2, 2026, and will vest over four years, with 25% of the underlying shares vesting on the one-year anniversary of the applicable vesting commencement date and the balance of the underlying shares vesting monthly thereafter over 36 months. The RSUs will vest over four years, with 25% of the RSUs vesting on each anniversary of the applicable vesting commencement date. Vesting for both the stock options and RSUs is subject to the new employee’s continued service relationship with the Company through the applicable vesting dates. The awards are subject to the terms and conditions of the Company’s 2024 Inducement Plan and the terms and conditions of an applicable award agreement covering the grant.

About Immunome, Inc.

Immunome is a clinical-stage targeted oncology company committed to developing first-in-class and best-in-class cancer therapies. We are advancing an innovative portfolio of therapeutics, supported by a leadership team with deep experience in the design, development, and commercialization of cutting-edge therapies, including antibody-drug conjugates. Our pipeline includes varegacestat, an investigational, oral, once-daily gamma secretase inhibitor for which an NDA has been accepted by the U.S. FDA; IM-1021, a clinical-stage ROR1 ADC; IM-1617, a clinical-stage solid tumor ADC; IM-3050, a clinical-stage FAP-targeted radiotherapy; and IM-1340, an IND-cleared solid tumor ADC. We are also advancing a broad portfolio of early-stage ADCs pursuing undisclosed solid tumor targets. For more information, visit www.immunome.com .

View source version on businesswire.com: https://www.businesswire.com/news/home/20261106493528/en/

NEWS DETAILS

View all news

Immunome to Present Initial First-in-Human Clinical Data for IM-1021 in Advanced B-Cell Lymphomas at ASH 2026

November 4, 2026

  • Initial results demonstrate objective responses across all dose levels evaluated in heavily pretreated patients with B-cell non-Hodgkin lymphoma (B-NHL)

  • Objective response rate of 53% observed in response-evaluable patients with B-NHL, including complete responses

BOTHELL, Wash. – Immunome, Inc. (Nasdaq: IMNM), a clinical-stage targeted oncology company committed to developing first-in-class and best-in-class cancer therapies, today announced the presentation of initial first-in-human clinical data from the ongoing Phase 1 study of IM-1021, an investigational ROR1-targeted antibody-drug conjugate (ADC) for the treatment of advanced B-cell lymphomas, at the 68th American Society of Hematology (ASH) Annual Meeting.

The poster will include initial results demonstrating responses across all dose levels evaluated in heavily pretreated patients with B-cell non-Hodgkin lymphoma (B-NHL). Among 19 response-evaluable patients with B-NHL, the objective response rate (ORR) was 53% (10/19), including five complete responses (CRs) and five partial responses (PRs). Among 11 response-evaluable patients with diffuse large B-cell lymphoma (DLBCL), the ORR was 64% (7/11), including three CRs and four PRs.

“At this interim read, we were encouraged to see clinical activity with IM-1021 in these heavily pretreated patients, including patients whose disease had progressed following T-cell redirecting therapies,” said Bob Lechleider, M.D., Chief Medical Officer of Immunome. “These early results support our dose optimization efforts as we work to advance IM-1021 and further evaluate its potential for patients with B-cell lymphomas. The study is ongoing, and we look forward to presenting an updated dataset at ASH.”

As of the June 26, 2026, abstract data cutoff, 35 patients had received IM-1021, including 25 patients with B-NHL. Treatment-emergent adverse events (TEAEs) were reported in 92% of B-NHL patients. Grade 3 TEAEs occurred in 52% of B-NHL patients, of which the most common was neutropenia (44%). The patients with B-NHL had received a median of four prior lines of therapy, and prior T-cell redirecting therapy was common. Responses were observed across all dose levels tested. Dose optimization across multiple dosing regimens remains ongoing.

Presentation Details

Title**:** Initial results from first-in-human study of IM-1021, a ROR1-targeted antibody-drug conjugate with TOP1-inhibitor payload, in adults with advanced B-cell lymphomas

Presenter**:** Dr. Krish Patel (Sarah Cannon Research Institute)

Session**:** 629: Aggressive Lymphomas, Non-Cellular Immunotherapy including Bispecific Antibodies: Poster III

Publication Number**:** 5457

Location: MCCNO – Hall F

Date/Time**:** December 14, 2026, 6:00p.m. – 8:00p.m.

About the IM-1021-101 Trial

The Phase 1 IM-1021-101 study (ClinicalTrials.gov Identifier: NCT06823167) is an ongoing, first-in-human, open-label, multinational, multicenter dose-escalation and expansion study evaluating IM-1021 in patients with advanced B-cell lymphomas and advanced solid tumors. The study is designed to evaluate the safety and tolerability of IM-1021 and select recommended dose(s) for further study, as well as characterize preliminary antitumor activity and pharmacokinetics.

About IM-1021

IM-1021 is an investigational ROR1-targeted ADC currently being evaluated in a Phase 1 study in patients with advanced B-cell lymphomas. ROR1 is expressed in liquid and solid tumors but is largely absent in most mature tissues. IM-1021 incorporates an antibody designed to promote internalization and Immunome’s proprietary TOP1 inhibitor payload, HC74. Immunome designed IM-1021 to optimize ADC-mediated killing of ROR1-positive tumor cells. The company initiated enrollment in the Phase 1 study in the first quarter of 2025.

About Immunome, Inc.

Immunome is a clinical-stage targeted oncology company committed to developing first-in-class and best-in-class cancer therapies. We are advancing an innovative portfolio of therapeutics, supported by a leadership team with deep experience in the design, development, and commercialization of cutting-edge therapies, including antibody-drug conjugates. Our pipeline includes varegacestat, an investigational, oral, once-daily gamma secretase inhibitor for which an NDA has been accepted by the U.S. FDA; IM-1021, a clinical-stage ROR1 ADC; IM-1617, a clinical-stage solid tumor ADC; IM-3050, a clinical-stage FAP-targeted radiotherapy; and IM-1340, an IND-cleared solid tumor ADC. We are also advancing a broad portfolio of early-stage ADCs pursuing undisclosed solid tumor targets. For more information, visit www.immunome.com .

Cautionary Statement Regarding Forward-Looking Statements

Statements in this press release that are not purely historical in nature are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. We use words such as “will,” “committed to,” “look forward,” “potential,” and similar expressions to identify these forward-looking statements. These forward-looking statements include statements regarding the potential of IM-1021, including its potential therapeutic benefits; the continued clinical development and dose optimization of IM-1021; the expected presentation of an updated dataset at ASH; and other statements regarding management’s intentions, plans, beliefs, expectations or forecasts for the future.

These forward-looking statements are based on Immunome’s current expectations and involve assumptions that may never materialize or may prove to be incorrect; consequently, actual results may differ materially from those expressed or implied due to a number of factors, including risks related to the clinical development of IM-1021, including the possibility that preliminary clinical results may not be indicative of future results; risks related to the safety and efficacy of IM-1021; risks related to the timing and results of ongoing clinical studies; Immunome’s ability to grow and advance its pipeline and execute on its business plan; and other risks and uncertainties included under the caption “Risk Factors” in Immunome’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2026, filed with the Securities and Exchange Commission on August 11, 2026.

These documents can also be accessed on Immunome’s website at www.immunome.com by clicking on the link “Financials” under the “Investors” tab. The forward-looking statements included in this press release are made only as of the date of this press release. Except as required by law, Immunome assumes no obligation and does not intend to update any forward-looking statements included in this press release.

View source version on businesswire.com: https://www.businesswire.com/news/home/20261104589966/en/

Prompts

Immunome, Inc. (ticker IMNM), listed in United States.

ETFs Holding Immunome, Inc.

ETF Weight in ETF Shares Market value As of
CANC 3.00% 230,958 $ 6.331M Aug 31, 2026
TMED 1.38% 15,009 $ 318.041K Jun 30, 2026
MMSC 0.33% 9,249 $ 162.875K Nov 16, 2026
FSCC 0.26% 34,988 $ 959.021K Aug 31, 2026
SCDS 0.26% 1,402 $ 24.086K Nov 17, 2026
RESM 0.07% 120 $ 2,542.80 Jun 30, 2026
VFMO 0.06% 44,285 $ 1.214M Aug 31, 2026
MSSM 0.01% 3,695 $ 101.28K Aug 31, 2026
DFAS 0.01% 156,733 $ 2.931M Nov 12, 2026
DFUS 0.00% 47,755 $ 893.019K Nov 12, 2026
DFSU 0.00% 4,072 $ 76.146K Nov 12, 2026
DFAU 0.00% 18,562 $ 347.109K Nov 12, 2026
DFAC 0.00% 93,975 $ 1.757M Nov 12, 2026
DCOR 0.00% 24,691 $ 461.722K Nov 12, 2026
AVSC 0.00% 8,201 $ 144.42K Nov 16, 2026
NTRL short 0.00% -8,622 $ 0.00 Nov 16, 2026